Forskning ved Københavns Universitet - Københavns Universitet

Forside

International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Jennifer J. Mueller
  • Henrik Lajer
  • Berit Jul Mosgaard
  • Slim Bach Hamba
  • Philippe Morice
  • Sebastien Gouy
  • Yaser Hussein
  • Robert A. Soslow
  • Brooke A. Schlappe
  • Qin C. Zhou
  • Alexia Iasonos
  • Høgdall, Claus Kim
  • Alexandra Leary
  • Roisin E. O'Cearbhaill
  • Nadeem R. Abu-Rustum

Objective We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes. Methods This was a retrospective review spanning 1976-2014. All tumors were centrally reviewed by an expert gynecologic pathologist. Each center used a combination of clinical and histologic criteria to confirm a PMOC diagnosis. Data were abstracted from medical records, and a deidentified dataset was compiled and processed at a single institution. Appropriate statistical tests were performed. Results Two hundred twenty-two patients with PMOC were identified; all had undergone primary surgery. Disease stage distribution was as follows: stage I, 163 patients (74%); stage II, 8 (4%); stage III, 40 (18%); and stage IV, 10 (5%). Ninety-nine (45%) of 219 patients underwent lymphadenectomy; 41 (19%) of 215 underwent fertility-preserving surgery. Of the 145 patients (65%) with available treatment data, 68 (47%) had received chemotherapy - 55 (81%) a gynecologic regimen and 13 (19%) a gastrointestinal regimen. The 5-year progression-free survival (PFS) rates were 80% (95% confidence interval [CI], 73%-85%) for patients with stage I to II disease and 17% (95% CI, 8%-29%) for those with stage III to IV disease. The 5-year PFS rate was 73% (95% CI, 50%-86%) for patients who underwent fertility-preserving surgery. Conclusions Most patients (74%) presented with stage I disease. Nearly 50% were treated with adjuvant chemotherapy using various regimens across institutions. The PFS outcomes were favorable for those with early-stage disease and lower but acceptable for those who underwent fertility preservation.

OriginalsprogEngelsk
TidsskriftInternational Journal of Gynecological Cancer
Vol/bind28
Udgave nummer5
Sider (fra-til)915-924
Antal sider10
ISSN1048-891X
DOI
StatusUdgivet - 2018

ID: 220861242